---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076843"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:40:51.292398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tectonic Q4 net loss $19.2M; TX45 Phase 1b positive, TX2100 Phase 1a started

## Summary
- Q4 net loss $19.2M (vs $12.4M YoY); R&D expenses $16.3M on advancing pipeline.
- Cash and equivalents $253.8M as of Dec 31, 2025; expected cash runway into Q4 2028.
- TX45 Phase 1b in PH-HFrEF showed 29.2% reduction in PCWP and 17.3% cardiac output improvement.
- TX2100 Phase 1a in HHT randomized first subject Feb 2026; topline results expected Q4 2026.
- François Nader appointed independent director effective April 1, 2026, to also serve as Board Chair.

## SEC filing metadata
- accession: 0001193125-26-076843
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/0001193125-26-076843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/tecx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076843
- JSON: https://secwatch.observer/filing/0001193125-26-076843.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.